Trinity Biotech (NASDAQ: TRIB) has announced compelling clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its next-generation continuous glucose monitoring (CGM) technology—CGM+.
According to Trinity, for the first time, trial data confirms that Trinity’s redesigned proprietary needle-free glucose sensor delivers accurate glucose readings across a full 15-day wear period without the need for finger-stick calibration, while also facilitating an innovative CGM design that reduces disposable components, significantly lowering the cost of care compared to current leading market products.
In a statement, John Gillard, CEO of Trinity, commented, “The elimination of the requirement for finger-stick calibration was achieved through a combination of sensor design modifications, refined signal processing, and proprietary enhancements to sensor operation. With this, we’ve successfully addressed the most uncertain technical hurdle and brought our glucose sensor in line with the standards of market leaders—but critically with a highly differentiated product architecture that promises to be more affordable, reusable, and sustainable while also supporting the single device integration of heart activity, body temperature, and physical activity data.”
